CBG vs. CBD for ALS: What the Research Actually Shows

High-Level Clinical Data

• Target Compound: CBG (Cannabigerol) is emerging as a candidate for neuroprotection due to its role as a PPARγ agonist.
• Critical Terpenes: Beta-Caryophyllene supports the management of neuropathic pain, while Myrcene may serve as a muscle relaxant for spasticity.
• Pathological Mechanism: Researchers are evaluating cannabinoids for their potential to mitigate glutamate excitotoxicity.
• Standardized Dosing: The 1:1:1 (CBD:CBG:THC) ratio is becoming a clinical benchmark for balancing therapeutic utility with patient safety.

The Neuroprotective Duel: CBG vs. CBD

While CBD remains an industry staple for systemic inflammation, its role in ALS is supportive. It functions as an antioxidant and modulates overactive microglia—the immune cells that create a toxic environment in the ALS-affected brain. CBD acts as a secondary defense layer for anxiety and systemic inflammation.

CBG (Cannabigerol) is a primary focus for those looking to address neurodegenerative progression. As the precursor molecule to other cannabinoids, CBG demonstrates potential in protecting neurons from oxidative stress-induced death.

• Mechanism of Action: CBG acts as a PPARγ agonist.
• Clinical Value: Activating these receptors may reduce inflammatory gene expression within the central nervous system.
• Market Trend: Product developers are moving toward isolated CBG, creating specialized "neuro-blends" tailored for ALS and Parkinson’s patients.

Functional Terpene Profiles: Myrcene vs. Beta-Caryophyllene

Terpenes are physiological drivers that dictate how a cannabinoid product performs in the body. ALS patients require specific concentrations to manage distinct, life-altering symptoms.

Myrcene for Spasticity

Myrcene is prevalent in the market, but its utility in ALS is specific: it increases the permeability of the blood-brain barrier. In practice, myrcene may act as a muscle relaxant, offering a plant-based adjunct to pharmaceuticals like baclofen. It is a preferred choice for patients struggling with severe, rigid limb stiffness.

Beta-Caryophyllene for Neuropathic Pain

Beta-caryophyllene (BCP) is unique. Because it binds directly to CB2 receptors, it functions as a hybrid between a terpene and a cannabinoid.

• Pain Management: BCP is often used for the "zapping" or burning sensations common in neuropathic ALS pain.
• Neuro-inflammation: BCP may reduce pro-inflammatory cytokines in the brain.
• Standardization: High-BCP profiles are useful for patients who need nerve-specific relief without the sedation of myrcene.

Addressing Glutamate Excitotoxicity

Glutamate excitotoxicity is a hallmark of ALS. When glutamate levels build up between cells, they overstimulate and kill motor neurons. This is the biological mechanism targeted by Riluzole.

Cannabinoids act as "dimmer switches" for this process. THC and CBD may inhibit the over-release of glutamate by activating CB1 receptors on the presynaptic neuron. This interaction indicates that full-spectrum formulations may assist in modulating the chemical imbalances that drive disease progression. Broad-spectrum extracts are often used to support the necessary glutamate-cannabinoid feedback loop.

The 1:1:1 Ratio: The New Industry Standard

Clinical experience points to a balanced ratio as an effective strategy for managing ALS symptoms while minimizing risk. The 1:1:1 (CBD:CBG:THC) ratio is a common standard for therapeutic stability:

1. CBD (1 Part): Neutralizes THC-induced anxiety and manages systemic inflammation.
2. CBG (1 Part): Provides targeted neuroprotection through PPARγ activation.
3. THC (1 Part): Delivers relief for pain, muscle spasticity, and appetite loss.

Dosing at this ratio limits cognitive impairment. In ALS care, where maintaining balance and preventing falls is a priority, avoiding over-intoxication is as important as the medicine itself.

Delivery Systems and Disease Progression

As ALS progresses, dysphagia (difficulty swallowing) becomes a hurdle. Traditional capsules and edibles carry a choking risk.

• Sublingual Tinctures: These bypass the digestive system, entering the bloodstream via the oral mucosa.
• Nano-Emulsification: This is the current frontier. Nano-emulsified sublinguals are water-soluble and absorb quickly.
• Respiratory Safety: While vaping provides rapid relief for acute cramps, it is often contraindicated for patients with reduced lung capacity. Water-soluble sublinguals offer the speed of inhalation without the respiratory strain.

Clinical Risks and Liability

Cannabis must be integrated into a pharmaceutical regimen with professional oversight. CBD is a known inhibitor of the CYP450 enzyme in the liver, which can alter the metabolism of common ALS co-medications, including blood thinners and antidepressants.

The primary clinical risk in ALS remains the fall risk associated with THC. Formulations should prioritize high-CBD/CBG concentrations with a strictly controlled THC ceiling to ensure that symptom management does not compromise patient mobility.

---

Legal Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always seek the advice of a physician regarding a medical condition. Efficacy has not been confirmed by FDA-approved research. Check your local laws regarding cannabis and terpene use.

Sources

1. Valdeolivas S, Navarrete C, Cantarero I, Bellido ML, Muñoz E, Sagredo O. (2015). Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-treated mice. Neurotherapeutics. 12(1):185-99. PubMed

2. Sagredo O, Pazos MR, Satta V, Ramos JA, Pertwee RG, Fernández-Ruiz J. (2011). Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease. J Neurosci Res. 89(9):1509-18. PubMed

3. Russo EB. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 163(7):1344-64. PubMed

4. Bilsland LG, Dick JR, Pryce G, Petrosino S, Di Marzo V, Baker D, Greensmith L. (2006). Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J. 20(7):1003-5. PubMed

5. Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee R, Mechoulam R, Martínez-Orgado J. (2013). Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol. 75(2):323-33. PubMed